DEUTETRABENAZINE: UPDATE ON FIRST TIME USE OF SD-809 IN HUNTINGTON'S DISEASE (FIRST-HD) AND ALTERNATIVE FOR REDUCING CHOREA IN HUNTINGTON'S DISEASE (ARC-HD)

被引：0
|
作者：
Testa, Claudia [1 ]
机构：
[1] Huntington Study Grp, Rochester, NY USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2016年 / 87卷
关键词：
D O I：
10.1136/jnnp-2016-314597.286
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
M1
引用
收藏
页码：A101 / A101
页数：1
相关论文
共 39 条
  • [21] Concomitant Use of Antidepressants and Neuroleptics with Tetrabenazine during Treatment of Huntington's Disease (HD)
    Clarence-Smith, Kathleen
    Shen, Vivienne
    Hunter, Christine
    Jankovic, Joseph
    NEUROLOGY, 2012, 78
  • [22] Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study
    Ogilvie, Amy C.
    Schultz, Jordan L.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (07): : 1120 - 1125
  • [23] Impact of Chorea on Employment, Self-Care Activities, and Independency in Huntington's Disease (HD) Patients in the USA
    Claassen, Daniel
    DeCourcy, Jonathan
    Mellor, Jennifer
    Johnston, Charlotte
    Iyer, Ravi
    MOVEMENT DISORDERS, 2018, 33 : S76 - S77
  • [24] Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)
    Harris, Kate L.
    Kuan, Wei-Li
    Mason, Sarah L.
    Barker, Roger A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (06): : 622 - 630
  • [25] Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD
    Stimming, Erin Furr
    Claassen, Daniel O.
    Sen, Ginny P.
    Klepitskaya, Olga
    Serbin, Michael
    Kim, Hyunwoo
    Hinton, Sean C.
    Haubenberger, Dietrich
    NEUROLOGY AND THERAPY, 2025,
  • [26] The use of olanzapine for movement disorder in Huntington's disease: a first case report
    Dipple, HC
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (01): : 123 - 124
  • [27] Impaired motor speech performance in premotor stages of Huntington's disease (HD) over time - A longitudinal investigation
    Skodda, S.
    Schlegel, U.
    Hoffmann, R.
    Saft, C.
    MOVEMENT DISORDERS, 2014, 29 : S217 - S217
  • [28] VMAT 2 Inhibitor and Antipsychotic Use in Individuals with Huntington's Disease Using Enroll-HD Data
    Furr-Stimming, Erin
    Zhu, Liang
    Rocha, Natalia Pessoa
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 35 - 35
  • [29] IMPAIRED MOTOR SPEECH PERFORMANCE IN PREMOTOR STAGES OF HUNTINGTON'S DISEASE (HD) OVER TIME - A LONGITUDINAL INVESTIGATION
    Saft, C.
    Schlegel, U.
    Hoffmann, R.
    Skodda, S.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A57 - A58
  • [30] Evolving inclusion criteria in early manifest Huntington's disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial
    Furr-Stimming, Erin
    Testa, Claudia
    Larson, Paul
    Ross, Christopher A.
    Lonser, Russell
    Samii, Ali
    Cooper, David L.
    Ying, Sarah
    Clarkin, Marcie
    Sawyer, Eileen K.
    Reilmann, Ralf
    NEUROLOGY, 2021, 96 (15)
1234